medigraphic.com
ISSN 1727-897X (Electronic)

2022, Number 1

<< Back Next >>

Medisur 2022; 20 (1)

Health-related quality of life in patients with multiple sclerosis

Vázquez-Gómez LA, Hidalgo MC, Beltrán GBM, Broche-Pérez Y, Mederos-Herrera AM

Language: Spanish
References: 15
Page: 44-51
PDF size: 327.75 Kb.


ABSTRACT

Background: multiple sclerosis is a disease characterized by outbreaks of disability in any functional system that are produced by inflammation and demyelination of the central nervous system.
Objective: to determine the health-related quality of life in patients with multiple sclerosis.
Methods: a quasi-experimental, prospective longitudinal study with all patients diagnosed with multiple sclerosis with follow-up in Villa Clara during the period from 2017 to 2019. The study population consisted of 86 patients who were part of a multidisciplinary follow-up strategy.
Results: regarding the modifications of the mental and physical component of the health state, it was observed that the mean score was 30.4 ± 9.7 and 39.9 ± 10.2 respectively before the strategy and 38.8 ± 9.3 and 51.5 ± 9.3 later respectively; so they moved to higher levels. On the visual impairment impact scale, the mean was 10.8 ± 2.2 before and 7.1 ± 2.8 after. Regarding the modifications in the mental health inventory, it was 58.1 ± 14.8 before and 47.2 ± 15.1 after. There was improvement in the impact of fatigue; pain effect; sexual satisfaction; bladder control; bowel control; impact of visual impairment; perceived cognitive deficit; mental health and social support.
Conclusions: satisfactory modifications were achieved in the perceived quality of life scale, in the mental and physical health components, for which there was an improvement in health-related quality of life.


REFERENCES

  1. Rivera VM. Multiple Sclerosis: A Global Concern with multiple challenges in an Era of advanced therapeutic complex molecules and biological medicines. Biomedicines. 2018;6:112.

  2. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391:1622-36.

  3. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019;92:E1029-40.

  4. Pérez-Carmona N, Fernández-Jover E, Sempere ÁP. Epidemiology of multiple sclerosis in Spain. Rev Neurol. 2019;69:32-8.

  5. Toro J, Cárdenas S, Fernando Martínez C, Urrutia J, Díaz C. Multiple sclerosis in Colombia and other Latin American Countries. Mult Scler Relat Disord. 2013;2:80-9.

  6. Gracia F, Armién B, Rivera V, Valverde A, Rodríguez V, Monterrey P, et al. Multiple Sclerosis in Central American and Spanish Caribbean Region: Should it be Recognized as a Public Health Problem? Collaborative Multiple Sclerosis Group of Central America and Spanish Caribbean Region (CMSG). J Epid Prev Med. 2017;3:134.

  7. Orozco-González C, Vagner-Ramírez B, Salas-Zapata C. Calidad de vida en pacientes con esclerosis múltiple atendidos en una institución de salud de Medellín, Colombia. Univ Salud [Internet]. 2019 [citado 12/06/2021];21(3):[aprox. 21 p.]. Disponible en: https://revistas.udenar.edu.co/index.php/usalud/article/view/3737/5453

  8. Boucher F, Baumstarck K, Acquadro C. Challenges In Translating The Multiple Sclerosis International Quality of Life (Musiqol) Questionnaire In 57 Languages. Value Heal. 2015;18(7):A762.

  9. Gracia F, Larreategui M, Rodríguez G. Costs of multiple sclerosis in Panama from societal, patient perspectives and health related quality of life. PLoS One. 2018;13(10):1-12.

  10. Méndez Barbosa EA, Guancha Aza LJ, Ávila Gelvez JA, Gómez Alfonzo AE. Calidad de vida en pacientes con esclerosis múltiple. Reciamuc[Internet]. 2021[citado 15/06/2021];5(2)[aprox. 8 p.]. Disponible en: https://reciamuc.com/index.php/RECIAMUC/article/view/639/982

  11. Vázquez-Gómez L, Hidalgo Mesa C, Beltrán González B, Broche-Pérez Y, Valdés Morales , Mederos-Herrera A. Estrategia para el seguimiento multidisciplinario a pacientes con esclerosis múltiple. EDUMECENTRO[Internet]. 2021[citado 02/07/2021];13(3):[aprox. 22 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S2077-28742021000300042&lng=en&nrm=iso&tlng=es

  12. Rojas E, Alva A, Montalvan V. Cambios clínicos de la esclerosis múltiple según modificación de los criterios de McDonald. Hospital Almenara, 2001-2015. An Fac Med [Internet]. 2019[citado 25/06/2021];80(1):[aprox. 14 p.]. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832019000100006

  13. Mesa Walwyn I, Bravo Acosta T. Influencia del tratamiento neurorrehabilitador en la calidad de vida de pacientes con esclerosis múltiple. Rev Cubana de Med Fís y Rehabilit [Internet]. 2018[citado 25/06/2021];10(2):[aprox. 17 p.]. Disponible en: http://www.revrehabilitacion.sld.cu/index.php/reh/article/view/293/402

  14. Freeman JA, Hendrie W, Creanor S. Standing up in multiple sclerosis (SUMS): Protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis. BMC Neurol. 2016;16(1):1-10.

  15. Yalachkov Y, Soydas D, Bergmann J. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019;30:33-7.




2020     |     www.medigraphic.com